These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25637316)

  • 1. IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment.
    Kinose Y; Sawada K; Makino H; Ogura T; Mizuno T; Suzuki N; Fujikawa T; Morii E; Nakamura K; Sawada I; Toda A; Hashimoto K; Isobe A; Mabuchi S; Ohta T; Itai A; Morishige K; Kurachi H; Kimura T
    Mol Cancer Ther; 2015 Apr; 14(4):909-19. PubMed ID: 25637316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Novel IκB Kinase β Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice.
    Sawada I; Hashimoto K; Sawada K; Kinose Y; Nakamura K; Toda A; Nakatsuka E; Yoshimura A; Mabuchi S; Fujikawa T; Itai A; Kimura T
    Int J Gynecol Cancer; 2016 May; 26(4):610-8. PubMed ID: 26905334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis.
    Yin X; Wang X; Shen B; Jing Y; Li Q; Cai MC; Gu Z; Yang Q; Zhang Z; Liu J; Li H; Di W; Zhuang G
    Sci Rep; 2016 Aug; 6():31079. PubMed ID: 27498762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    Devapatla B; Sharma A; Woo S
    PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
    Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sp1 inhibition-mediated upregulation of VEGF 165 b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549.
    Li ZY; Zhu F; Hu JL; Peng G; Chen J; Zhang S; Chen X; Zhang RG; Chen LJ; Liu P; Luo M; Sun ZH; Ren JH; Huang LL; Wu G
    Tumour Biol; 2011 Aug; 32(4):677-87. PubMed ID: 21442281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
    Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
    Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition.
    Yagi H; Yotsumoto F; Miyamoto S
    Mol Cancer Ther; 2008 Oct; 7(10):3441-51. PubMed ID: 18852147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
    Duncan TJ; Al-Attar A; Rolland P; Scott IV; Deen S; Liu DT; Spendlove I; Durrant LG
    Clin Cancer Res; 2008 May; 14(10):3030-5. PubMed ID: 18483368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
    Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
    Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
    von Marschall Z; Scholz A; Cramer T; Schäfer G; Schirner M; Oberg K; Wiedenmann B; Höcker M; Rosewicz S
    J Natl Cancer Inst; 2003 Mar; 95(6):437-48. PubMed ID: 12644537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.
    Hernandez L; Hsu SC; Davidson B; Birrer MJ; Kohn EC; Annunziata CM
    Cancer Res; 2010 May; 70(10):4005-14. PubMed ID: 20424119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.
    Kaimal R; Aljumaily R; Tressel SL; Pradhan RV; Covic L; Kuliopulos A; Zarwan C; Kim YB; Sharifi S; Agarwal A
    Cancer Res; 2013 Apr; 73(8):2457-2467. PubMed ID: 23423981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paris saponin II inhibits human ovarian cancer cell-induced angiogenesis by modulating NF-κB signaling.
    Yang M; Zou J; Zhu H; Liu S; Wang H; Bai P; Xiao X
    Oncol Rep; 2015 May; 33(5):2190-8. PubMed ID: 25760800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
    Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
    J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
    Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.